Previous close | 12.16 |
Open | 12.69 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 12.37 - 12.89 |
52-week range | 3.22 - 18.31 |
Volume | |
Avg. volume | 53,275 |
Market cap | 17.158M |
Beta (5Y monthly) | 0.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or
SAN CARLOS, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences: Chardan Annual Genetic Medicines & Cell Therapy Manufacturing Summit Fireside Chat: April 30, 2024 at 2:30 p.m. ETVirtual The Citizens JMP Life Scienc
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline MelanomaSAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that clinical data for lifileucel in combination with pembrolizuma